Hospital Corporation of China Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Hospital of China te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Healthcare winstgroei	18.5%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

We Think Hospital Corporation of China (HKG:3869) Can Stay On Top Of Its Debt

Oct 01

Not Many Are Piling Into Hospital Corporation of China Limited (HKG:3869) Stock Yet As It Plummets 28%

Aug 30

We Think Hospital Corporation of China's (HKG:3869) Profit Is Only A Baseline For What They Can Achieve

Apr 29

Hospital Corporation of China Limited (HKG:3869) Stock Rockets 33% But Many Are Still Ignoring The Company

Jun 30

Hospital Corporation of China (HKG:3869) Hasn't Managed To Accelerate Its Returns

May 17

Does Hospital Corporation of China (HKG:3869) Have A Healthy Balance Sheet?

Apr 12

Would Shareholders Who Purchased Hospital Corporation of China's (HKG:3869) Stock Three Years Be Happy With The Share price Today?

Mar 08

Should You Be Impressed By Hospital Corporation of China's (HKG:3869) Returns on Capital?

Jan 14

Hospital Corporation of China (HKG:3869) Takes On Some Risk With Its Use Of Debt

Dec 10

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Hospital Corporation of China onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

SEHK:3869 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2024	1,429	-14	55	78	N/A
3/31/2024	1,429	59	61	80	N/A
12/31/2023	1,428	131	67	83	N/A
9/30/2023	1,374	102	122	136	N/A
6/30/2023	1,320	73	177	190	N/A
3/31/2023	1,231	-204	152	167	N/A
12/31/2022	1,143	-481	126	143	N/A
9/30/2022	998	-424	81	96	N/A
6/30/2022	854	-367	36	49	N/A
3/31/2022	687	-324	77	91	N/A
12/31/2021	520	-281	117	133	N/A
9/30/2021	473	-245	132	146	N/A
6/30/2021	426	-210	146	159	N/A
3/31/2021	412	-307	110	121	N/A
12/31/2020	399	-404	73	83	N/A
9/30/2020	391	-435	75	86	N/A
6/30/2020	383	-467	76	88	N/A
3/31/2020	397	-158	64	76	N/A
12/31/2019	411	151	51	63	N/A
9/30/2019	414	110	57	72	N/A
6/30/2019	418	70	62	81	N/A
3/31/2019	401	10	77	102	N/A
12/31/2018	384	-50	91	122	N/A
6/30/2018	235	-53	30	49	N/A
3/31/2018	192	-40	N/A	48	N/A
12/31/2017	149	-27	N/A	47	N/A
6/30/2017	143	-5	N/A	75	N/A
3/31/2017	137	9	N/A	120	N/A
12/31/2016	131	23	N/A	164	N/A
9/30/2016	160	34	N/A	162	N/A
12/31/2015	143	51	N/A	7	N/A
12/31/2014	28	2	N/A	4	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van 3869 boven de spaarquote ( 2.3% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van 3869 naar verwachting sneller zal groeien dan de markt Hong Kong

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van 3869 naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van 3869 naar verwachting sneller zal groeien dan de markt Hong Kong.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van 3869 naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van 3869 naar verwachting over 3 jaar hoog zal zijn

Hospital Corporation of China Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Hospital Corporation of China Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Recent updates

We Think Hospital Corporation of China (HKG:3869) Can Stay On Top Of Its Debt

First half 2024 earnings released: CN¥0.14 loss per share (vs CN¥0.91 profit in 1H 2023)

Not Many Are Piling Into Hospital Corporation of China Limited (HKG:3869) Stock Yet As It Plummets 28%

Hospital Corporation of China Limited to Report First Half, 2024 Results on Aug 29, 2024

New minor risk - Market cap size

We Think Hospital Corporation of China's (HKG:3869) Profit Is Only A Baseline For What They Can Achieve

Hospital Corporation of China Limited, Annual General Meeting, Jun 20, 2024

New major risk - Financial position

Full year 2023 earnings released: EPS: CN¥0.96 (vs CN¥3.48 loss in FY 2022)

Hospital Corporation of China Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 22%

New minor risk - Share price stability

Investor sentiment improves as stock rises 26%

First half 2023 earnings released: EPS: CN¥0.91 (vs CN¥3.09 loss in 1H 2022)

Investor sentiment improves as stock rises 23%

First half 2023 earnings released: EPS: CN¥0.91 (vs CN¥3.08 loss in 1H 2022)

Hospital Corporation of China Limited to Report Q2, 2023 Results on Aug 30, 2023

New minor risk - Market cap size

Now 36% undervalued after recent price drop

New minor risk - Share price stability

Hospital Corporation of China Limited (HKG:3869) Stock Rockets 33% But Many Are Still Ignoring The Company

Full year 2022 earnings released: CN¥3.48 loss per share (vs CN¥2.03 loss in FY 2021)

Hospital Corporation of China Limited Announces Resignation of Lu Wenzuo as Executive Director

Less than half of directors are independent

First half 2022 earnings released: CN¥3.08 loss per share (vs CN¥2.47 loss in 1H 2021)

First half 2022 earnings released: CN¥3.09 loss per share (vs CN¥2.47 loss in 1H 2021)

Hospital Corporation of China Limited to Report Q2, 2022 Results on Aug 30, 2022

Hospital Corporation of China Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Hospital Corporation of China Limited, Annual General Meeting, Jun 22, 2022

Less than half of directors are independent

Full year 2021 earnings released: CN¥2.03 loss per share (vs CN¥2.93 loss in FY 2020)

Hospital Corporation of China Limited Announces Executive Changes

First half 2021 earnings released: CN¥2.47 loss per share (vs CN¥3.87 loss in 1H 2020)

Non Executive Director Zhiqiang Su has left the company

Hospital Corporation of China (HKG:3869) Hasn't Managed To Accelerate Its Returns

Full year 2020 earnings released: CN¥2.93 loss per share (vs CN¥1.09 profit in FY 2019)

Does Hospital Corporation of China (HKG:3869) Have A Healthy Balance Sheet?

Full year 2020 earnings released: CN¥2.93 loss per share (vs CN¥1.09 profit in FY 2019)

Hospital Corporation of China Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Would Shareholders Who Purchased Hospital Corporation of China's (HKG:3869) Stock Three Years Be Happy With The Share price Today?

New 90-day high: HK$11.38

Hospital Corporation of China Limited Announces Executive Changes

Should You Be Impressed By Hospital Corporation of China's (HKG:3869) Returns on Capital?

New 90-day low: HK$10.60

New 90-day low: HK$10.90

Hospital Corporation of China (HKG:3869) Takes On Some Risk With Its Use Of Debt

Hospital Corporation of China Limited Announces Management Changes

First half earnings released

Hospital Corporation of China Limited to Report First Half, 2020 Results on Aug 28, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven